These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24660225)

  • 1. Barriers to utilizing long-acting injectable antipsychotic medications.
    Getzen H; Beasley M; D'Mello DA
    Ann Clin Psychiatry; 2014 Feb; 26(1):33-8. PubMed ID: 24660225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to utilizing long-acting injectable antipsychotic medications.
    Getzen H; Beasley M; D'Mello DA
    Ann Clin Psychiatry; 2013 Nov; 25(4):E1-6. PubMed ID: 24199223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicians' attitudes toward the use of long-acting injectable antipsychotics.
    Samalin L; Charpeaud T; Blanc O; Heres S; Llorca PM
    J Nerv Ment Dis; 2013 Jul; 201(7):553-9. PubMed ID: 23817151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications.
    Aggarwal NK; Sernyak MJ; Rosenheck RA
    J Clin Psychopharmacol; 2012 Jun; 32(3):323-8. PubMed ID: 22544006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients.
    Kim SW; Lee YH; Jang JE; Yoo T; Kim JM; Shin IS; Yoon JS
    Int Clin Psychopharmacol; 2013 Mar; 28(2):80-6. PubMed ID: 23325306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
    Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
    J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral versus long-acting antipsychotics on social functioning: A psychiatrists' survey in India.
    Gundugurti PR; Nagpal R; Sheth A; Narang P; Gawande S; Singh V
    Asian J Psychiatr; 2017 Dec; 30():88-93. PubMed ID: 28843143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years.
    Patel MX; Haddad PM; Chaudhry IB; McLoughlin S; Husain N; David AS
    J Psychopharmacol; 2010 Oct; 24(10):1473-82. PubMed ID: 19477883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Explicit review of risperidone long-acting injection prescribing practice.
    Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
    J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focused Ethnographic Examination of Barriers to Use of Long-Acting Injectable Antipsychotics.
    Robinson DG; Subramaniam A; Fearis PJ; Shi R; Walsh M; Hanna LA; Kane JM
    Psychiatr Serv; 2020 Apr; 71(4):337-342. PubMed ID: 31847736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.
    Llorca PM; Abbar M; Courtet P; Guillaume S; Lancrenon S; Samalin L
    BMC Psychiatry; 2013 Dec; 13():340. PubMed ID: 24359031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia.
    Weiden PJ; Roma RS; Velligan DI; Alphs L; DiChiara M; Davidson B
    J Clin Psychiatry; 2015 Jun; 76(6):684-90. PubMed ID: 25939027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia.
    Potkin S; Bera R; Zubek D; Lau G
    BMC Psychiatry; 2013 Oct; 13():261. PubMed ID: 24131801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral.
    Offord S; Wong B; Mirski D; Baker RA; Lin J
    J Med Econ; 2013; 16(2):231-9. PubMed ID: 23163287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers to long-acting injectable atypical antipsychotic use in Japan: Insights from a comparative psychiatrist survey.
    Oguchi Y; Miyake N; Ando K
    Neuropsychopharmacol Rep; 2024 Jun; 44(2):417-423. PubMed ID: 38634351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Opinions about long-term treatment of schizophrenia among psychiatrist in Gdansk region].
    Gizińska D; Trzebiatowska IA
    Psychiatr Pol; 2002; 36(6 Suppl):243-8. PubMed ID: 12647445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining what practising clinicians believe about long-acting injectable antipsychotic medication.
    Miles SW; Wheeler A; Davies K
    Int J Psychiatry Clin Pract; 2011 Jun; 15(2):135-44. PubMed ID: 22121862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.